Peoples Financial Services CORP. decreased its holdings in shares of Bristol-Myers Squibb (NYSE: BMY – Get Rating) by 5.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,159 shares of the biopharmaceutical company stock after selling 2,200 shares during the period. Bristol-Myers Squibb comprises approximately 1.2% of Peoples Financial Services CORP.’s investment portfolio, making its stock its 21st largest holding. Peoples Financial Services CORP.’s holdings in Bristol-Myers Squibb were worth $ 2,714,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in BMY. Norges Bank purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at approximately $ 1,413,962,000. Primecap Management Co. CA lifted its position in shares of Bristol-Myers Squibb by 16.9% during the 4th quarter. Primecap Management Co. CA now owns 22,114,455 shares of the biopharmaceutical company stock valued at $ 1,378,836,000 after buying an additional 3,195,680 shares in the last quarter. Nordea Investment Management AB lifted its position in shares of Bristol-Myers Squibb by 20.8% during the 4th quarter. Nordea Investment Management AB now owns 18,130,455 shares of the biopharmaceutical company stock valued at $ 1,136,598,000 after buying an additional 3,124,811 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at approximately $ 150,857,000. Finally, Deutsche Bank AG lifted its position in shares of Bristol-Myers Squibb by 17.0% during the 4th quarter. Deutsche Bank AG now owns 15,372,985 shares of the biopharmaceutical company stock valued at $ 958,504,000 after buying an additional 2,232,347 shares in the last quarter. Hedge funds and other institutional investors own 73.07% of the company stock.
A number of research analysts have weighed in on the company. Raymond James lowered Bristol-Myers Squibb from an “outperform” rating to a “market perform” rating in a report on Friday, June 3rd. They noted that the move was a valuation call. Citigroup restated a “buy” rating and issued a $ 90.00 price objective on shares of Bristol-Myers Squibb in a report on Friday, June 3rd. BMO Capital Markets raised their price objective on Bristol-Myers Squibb from $ 87.00 to $ 92.00 in a report on Monday, May 2nd. Morgan Stanley decreased their price objective on Bristol-Myers Squibb from $ 66.00 to $ 64.00 and set an “underweight” rating on the stock in a report on Wednesday, April 6th. Finally, Wells Fargo & Company raised their price target on Bristol-Myers Squibb from $ 65.00 to $ 70.00 and gave the company an “equal weight” rating in a report on Tuesday, May 17th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company stock. According to data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of “Moderate Buy” and a consensus target price of $ 74.27.
Shares of BMY opened at $ 78.96 on Friday. The stock has a fifty day simple moving average of $ 75.96 and a two-hundred day simple moving average of $ 70.21. The company has a quick ratio of 1.23, a current ratio of 1.32 and a debt-to-equity ratio of 1.18. The company has a market capitalization of $ 168.11 billion, a PE ratio of 28.00, a price-to-earnings-growth ratio of 1.67 and a beta of 0.49. Bristol-Myers Squibb has a 52-week low of $ 53.22 and a 52-week high of $ 79.00.
Bristol-Myers Squibb (NYSE: BMY – Get Rating) last issued its quarterly earnings data on Friday, April 29th. The biopharmaceutical company reported $ 1.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $ 1.92 by $ 0.04. The firm had revenue of $ 11.65 billion during the quarter, compared to the consensus estimate of $ 11.34 billion. Bristol-Myers Squibb had a return on equity of 48.37% and a net margin of 13.31%. The company quarterly revenue was up 5.2% on a year-over-year basis. During the same period last year, the company earned $ 1.74 EPS. As a group, equities analysts anticipate that Bristol-Myers Squibb will post 7.56 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 1st. Investors of record on Friday, July 1st will be given a dividend of $ 0.54 per share. This represents a $ 2.16 dividend on an annualized basis and a dividend yield of 2.74%. The ex-dividend date of this dividend is Thursday, June 30th. Bristol-Myers Squibb’s payout ratio is 76.60%.
In other Bristol-Myers Squibb news, CEO Giovanni Caforio sold 30,000 shares of Bristol-Myers Squibb stock in a transaction dated Monday, June 13th. The stock was sold at an average price of $ 74.04, for a total value of $ 2,221,200.00. Following the completion of the transaction, the chief executive officer now directly owns 551,104 shares of the company stock, valued at approximately $ 40,803,740.16. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Sandra Leung sold 65,000 shares of Bristol-Myers Squibb stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $ 74.89, for a total value of $ 4,867,850.00. Following the completion of the transaction, the executive vice president now directly owns 308,627 shares of the company stock, valued at $ 23,113,076.03. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by company insiders.
Bristol-Myers Squibb Company Profile: (Get Rating)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke / systemic embolism in NVAF, and for the treatment of DVT / PE; Opdivo for anti-cancer indications; Pomalyst / Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE: BMY – Get Rating).
Receive News & Ratings for Bristol-Myers Squibb Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.